# Pembrolizumab and Olaparib in Cervical Cancer Patients

> **NCT04483544** · PHASE2 · TERMINATED · sponsor: **Baptist Health South Florida** · enrollment: 8 (actual)

## Conditions studied

- Cervical Cancer
- Cervical Carcinoma

## Interventions

- **DRUG:** pembrolizumab
- **DRUG:** olaparib

## Key facts

- **NCT ID:** NCT04483544
- **Lead sponsor:** Baptist Health South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-03
- **Primary completion:** 2024-12-12
- **Final completion:** 2024-12-12
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Poor accrual related to change in standard of care treatment for this population.
- **Last updated:** 2025-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04483544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04483544, "Pembrolizumab and Olaparib in Cervical Cancer Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04483544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*